Form 4: Neuphoria Director Receives RSU Grant

Neuphoria Therapeutics Director David Ian Wilson was granted 8,537 Restricted Stock Units as part of the company's annual remuneration policy.

Summary

• David Ian Wilson, a Director of Neuphoria Therapeutics Inc. (NEUP), was granted 8,537 Restricted Stock Units (RSUs) on January 20, 2026.
• Each RSU represents a contingent right to receive one share of common stock.
• This grant is made pursuant to the Company's Board of Directors annual remuneration policy.
• Following this transaction, David Ian Wilson beneficially owns 15,412 derivative securities (RSUs).
• The RSUs will fully vest subject to the reporting person's continuous service to the Company through the day prior to the next annual shareholder meeting (expected no later than December 15, 2026) or the effective date of a Change in Control of the Company.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of Restricted Stock Units to a director, which is a standard compensation practice. It aligns the director's interests with shareholders but does not contain information that would significantly alter the company's financial outlook or operational performance.

Positives

• The grant of Restricted Stock Units (RSUs) to Director David Ian Wilson aligns his interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• The grant is part of the company's established annual remuneration policy for its Board of Directors, indicating a structured approach to executive compensation.

Risks

• The RSUs are subject to forfeiture if the reporting person's continuous service to the company ceases before the vesting conditions are met.
• Vesting is contingent on the next annual shareholder meeting occurring by December 15, 2026, or a Change in Control, introducing specific future event dependencies.

Future Outlook

The vesting conditions for the granted RSUs indicate an expectation of continuous service from Director David Ian Wilson until at least the company's next annual shareholder meeting, anticipated no later than December 15, 2026, or until a potential Change in Control.

Industry Context

The grant of Restricted Stock Units to a director is a common practice in the biotechnology and pharmaceutical industry, as well as broader public markets, to incentivize long-term commitment and align leadership interests with shareholder value creation. This type of equity compensation is a standard component of director remuneration packages.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a widely accepted practice across various industries, including biotechnology, aligning with compensation strategies seen in companies like Amgen, Gilead Sciences, and Biogen, which frequently utilize equity awards to retain and motivate key personnel.
• The vesting schedule tied to continuous service and the next annual shareholder meeting is typical for such grants, comparable to structures observed in peer companies where director compensation is often phased or contingent on ongoing board participation and company performance milestones.
• The grant price of $0 for RSUs is standard, as these awards represent a right to receive shares rather than an option to purchase them, reflecting a direct equity award rather than a purchase opportunity.

Corporate Governance

Related Party Transactions

• Grant of 8,537 Restricted Stock Units to David Ian Wilson, a Director of Neuphoria Therapeutics Inc., as part of his annual remuneration.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value creation, as the value of the RSUs is tied to the company's stock performance.
• Management: Reinforces the compensation structure for the Board of Directors.

Next Steps

• Continued service of David Ian Wilson to Neuphoria Therapeutics Inc.
• Vesting of the 8,537 Restricted Stock Units upon meeting the specified conditions (continuous service until the day prior to the next annual shareholder meeting or a Change in Control).

Key Dates

Keywords

Neuphoria Therapeutics, NEUP, Form 4, Restricted Stock Units, RSU Grant, Director Compensation, Insider Transaction, Corporate Governance